Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eiken’s Novel Coronavirus Detection Reagent Kit Approved, with Launch Planned in Mid-April
April 1, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
- Ono Expands I/O Collaboration with Swiss Firm Numab
March 31, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- Healios to Boost Its Stake in US Biotech Athersys
March 31, 2020
- Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
- Daiichi Sankyo Shares Anti-Coronavirus Measures, Development Plan
March 30, 2020
- Daiichi Sankyo, Kitasato Pharma End Flu Vaccine Collaboration
March 30, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- US FDA Accepts Xofluza’s Granule Version, Pediatric Use for Review: Shionogi
March 30, 2020
- Kissei Licenses CG Oncology's Oncolytic Viral Therapy in Asia Excluding China
March 30, 2020
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- Eisai Files CTCL/PTCL Drug at MHLW Request
March 27, 2020
- Yoshindo Curbs Shipments of Tranexamic Acid as Coronavirus Hits API Supplies
March 27, 2020
- Ono, BMS Submit Opdivo/Yervoy Duo for NSCLC in Combination with Chemo
March 27, 2020
- Takeda to Introduce Fronteo’s Drug Discovery Support AI System
March 27, 2020
- Roche Diagnostics Files New Coronavirus Test in Japan
March 27, 2020
- Pfizer Japan Extends Voluntary Ban on Doctor Visits to April 10
March 27, 2020
- Otsuka’s PDE4 Inhibitor Difamilast Delivers Positive Data for Atopic Dermatitis in Japan PIII
March 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…